No products in the cart.
Toremifene Citrate Tablets
$1.00
Toremifene citrate (brand name Ovry), manufactured by Jiangsu Ascend Pharmaceutical Co., Ltd., is a selective estrogen receptor modulator (SERM) approved in China (NMPA No.H20243050, code?86901425001187). Each box contains 30 tablets (60mg each) in 3 blister cards (barcode 6953272600284). Strictly for laboratory research purposes only.
Description
Toremifene Citrate Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Toremifene Citrate Tablets (Ovry) |
| Strength | 60mg per tablet |
| Quantity | 10 tablets per blister × 3 blisters = 30 tablets per box |
| Dosage Form | Oral tablet |
| Approval No. | China NMPA?H20243050 |
| Product Code | 86901425001187 |
| Barcode | 6953272600284 |
| Manufacturer | Jiangsu Ascend Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only — Not for human use |
Mechanism of Action
Toremifene is a SERM that functions as an estrogen receptor antagonist in breast tissue, while having partial estrogenic effects in bones and lipid metabolism. It is widely used as a reference compound in estrogen-receptor assays and breast cancer model systems.
Research & Reference Data
Clinically approved for metastatic estrogen-receptor–positive breast cancer in post-menopausal women, at a dose of 60mg once daily.
Pharmacokinetics: nearly 100% oral bioavailability, half-life of 3–7 days, high protein binding (~99.7%). en.wikipedia.org
Known to prolong QT interval; commonly used in studies evaluating cardiac safety and receptor interactions. pubchem.ncbi.nlm.nih.gov+9dailymed.nlm.nih.gov+9dailymed.nlm.nih.gov+9
Research Applications
ER+ breast cancer cell models
Receptor binding and signaling assays
SERM comparative pharmacology
QT prolongation modeling and toxicity screening
Disclaimer
This product is provided strictly for laboratory research and development use only.
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 18 × 16 × 18 cm |
1 review for Toremifene Citrate Tablets
Related products
Regorafenib Tablets
Regorafenib (Reodixin®) is an oral multi-kinase inhibitor targeting angiogenesis, proliferation, metastasis, and tumor immunity. FDA-approved for several advanced solid tumors. Here offered as 40mg tablets in a 28-count bottle—strictly for laboratory research use only $1.00Limertinib Tablets
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M mutated non small cell lung cancer, including patients with brain metastases. $1.00Fulvestrant Faslodex
Fluvestrant (250mg/5ml) injectable solution, 2-vial set by EVER?Pharma Jena GmbH, Germany. A potent selective estrogen receptor degrader (SERD) used in advanced breast cancer research. $2.00Irinotecan Hydrochloride Liposome Injection
Irinotecan Hydrochloride Liposome Injection Du’EnYi® is China’s first domestically approved liposome-encapsulated irinotecan injection, equivalent to ONIVYDE®. Each 10mL vial contains 43mg irinotecan and is strictly for laboratory research use only—not for clinical or human application.Please consult the staff for other purposes. $1.00
mood –
The package is damaged, you need to resend it to me, thank you